[Clinical testing of iruxol ointment].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D002056:Burns / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005734:Gangrene / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007871:Leg Ulcer / Q000188:drug therapy; D008297:Male; D003012:Microbial Collagenase / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009824:Ointments; D010447:Peptide Hydrolases / Q000009:adverse effects / Q000627:therapeutic use*; D003668:Pressure Ulcer / Q000188:drug therapy; D014947:Wounds and Injuries / Q000188:drug therapy
D000891:Anti-Infective Agents, Local; D009824:Ointments; D002701:Chloramphenicol; D010447:Peptide Hydrolases; D003012:Microbial Collagenase
Bericht über die klinische Prüfung von Iruxol-Salbe.